CEO's Blog

Good morning!

The December 2008 issue of Wired magazine has a very interesting article, called Why Early Detection Is The Best Way To Beat Cancer , that I highly recommend.

It turns out that if we find cancer early, 90 percent survive. If we find cancer late, 10 percent survive. In reality, the statistics aren’t quite that simple (e.g., some cancer types are worse than others). But basically, those are the odds on average.

While there has been a small increase in cancer survival rates over the past 30 years, this is mainly due to early detection, not new chemotherapies or treatments. And yet, despite these proven results to save lives and lower healthcare costs, organizations like the National Cancer Institute typically spend a paltry 8 percent of research funds on early detection. A notable exception is the Canary Foundation , where 100 percent of donations go to early detection research. The Canary Foundation should be applauded (and supported!) for their dedication to early detection and emphasis on results.

The peer-reviewed scientific research on cancer biomarkers found in exhaled breath is compelling, suggesting that early detection is both possible and practical with breath analysis. So why isn't breath analysis in routine use today? Simply put, existing gas analysis technologies are expensive, bulky and hard-to-use, making them unsuitable for clinical applications.

All that is about to change with LifeSens , Picomole's patient-friendly and cost-effective technology for clinical breath analysis. LifeSens is capable of detecting more than 90% of all known breath biomarkers, with results obtained in minutes.

Could a single breath change the course of your life? You better believe it.

Yours truly,
John